- Home
- DCGO vs AVIR Comparison
DCGO vs AVIR Comparison
Compare DCGO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- AVIR
- Stock Information
- Founded
- DCGO 2015
- AVIR 2012
- Country
- DCGO United States
- AVIR United States
- Employees
- DCGO N/A
- AVIR N/A
- Industry
- DCGO Managed Health Care
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- DCGO Health Care
- AVIR Health Care
- Exchange
- DCGO Nasdaq
- AVIR Nasdaq
- Market Cap
- DCGO 327.4M
- AVIR 290.4M
- IPO Year
- DCGO N/A
- AVIR 2020
- Fundamental
- Price
- DCGO $3.42
- AVIR $3.59
- Analyst Decision
- DCGO Strong Buy
- AVIR Hold
- Analyst Count
- DCGO 5
- AVIR 1
- Target Price
- DCGO $6.10
- AVIR $6.88
- AVG Volume (30 Days)
- DCGO 431.0K
- AVIR 153.0K
- Earning Date
- DCGO 11-07-2024
- AVIR 11-06-2024
- Dividend Yield
- DCGO N/A
- AVIR N/A
- EPS Growth
- DCGO 393.09
- AVIR N/A
- EPS
- DCGO 0.28
- AVIR N/A
- Revenue
- DCGO $742,836,424.00
- AVIR N/A
- Revenue This Year
- DCGO $1.17
- AVIR N/A
- Revenue Next Year
- DCGO N/A
- AVIR N/A
- P/E Ratio
- DCGO $12.35
- AVIR N/A
- Revenue Growth
- DCGO 64.49
- AVIR N/A
- 52 Week Low
- DCGO $2.75
- AVIR $2.77
- 52 Week High
- DCGO $6.90
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- DCGO 53.79
- AVIR 50.72
- Support Level
- DCGO $3.20
- AVIR $3.31
- Resistance Level
- DCGO $3.47
- AVIR $3.49
- Average True Range (ATR)
- DCGO 0.15
- AVIR 0.12
- MACD
- DCGO 0.03
- AVIR 0.04
- Stochastic Oscillator
- DCGO 87.80
- AVIR 52.21
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).